TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif., May 7, 2026 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology, today announced late-breaking data to be presented at the 2026 SID Annual Meeting, taking place May 13-16 in Chicago. The data to be presented support the clinical rationale for […] The post TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis appeared first on TrexBio .